
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics demonstrated strong growth in its second quarter of fiscal year 2025, achieving a 17% increase in the sale of nanochannel array flowcells, with 7,233 units sold compared to 6,165 in the same quarter of the previous year. The company's adjusted revenue, which excludes discontinued clinical services and focuses on consumables and software, increased by 11% year-over-year, with consumables and software revenues specifically rising by 16%. Additionally, Bionano's expectations for new OGM installations have improved for fiscal year 2025, projecting 20-25 installations, up from a previous estimate of 15-20, further indicating favorable operational momentum.
Bears say
Bionano Genomics faces significant financial challenges as reflected in the projected sales per share of $6.50 and net cash of $3.28 per share, indicating potential weaknesses in revenue generation. Moreover, there are notable risks including lower-than-expected market uptake and utilization of its products, which may hinder its growth prospects. Additionally, the company's reliance on securing further capital to sustain operations adds to the overall negative outlook, further complicating its financial stability.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares